TORONTO and DALLAS, April 16,
2024 /CNW/ - Perimeter Medical Imaging AI, Inc.
(TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or
the "Company") – a commercial-stage medical technology company –
announced a newly published webinar, "Trends in Artificial
Intelligence (AI) and Innovators in Healthcare" featuring a
fireside chat with Anantha
Kancherla, former head of Meta's AI platform, and current
member of Perimeter's Board, alongside Perimeter's CEO,
Adrian Mendes.
Adrian Mendes, Perimeter's Chief
Executive Officer stated, "The ability to use AI to make products
more useful for customers is going to differentiate successful
companies from those who fail. With this in mind, Perimeter has
built world-class leadership on its Board, the management team, and
the engineering department. This webinar showcases the depth of
Perimeter's knowledge to apply machine learning models and
artificial intelligence tools to our pipeline of products – both
existing and still in development. Further, we have – and continue
to grow – a large proprietary image data set, which allows us to
truly capture the value of AI with our ability to train models in a
way that is very hard for other companies to replicate."
Webinar Details
Title: Trends in Artificial Intelligence (AI) and
Innovators in Healthcare: Fireside Chat with Perimeter Medical
Imaging AI
Host: Martin Gagel, Radius Research
Speakers:
Adrian Mendes,
CEO, Perimeter Medical AI
Anantha Kancherla, VP, Advanced
Driver Assistance Systems, GM Motors
Link: View webinar here
Anantha Kancherla is
vice president of advanced driver-assistance systems at GM Motors.
Previously Anantha was Engineering Director at Meta, where he was
head of its AI platform. Prior to Meta, as VP of Engineering at
Lyft, Anantha led the Level5 software team responsible for building
the self-driving car. Anantha previously worked on Windows at
Microsoft focusing on DirectX, Graphics and UI. In his former role
at Facebook, Anantha participated in pioneering the building of
mobile software at scale for over a billion users all over the
world. Anantha obtained a B.Tech in Computer Science and
Engineering from the Indian Institute of
Technology, and a MS degree in Computer Science from the
University of North Carolina Chapel
Hill.
Adrian Mendes is
Chief Executive Officer at Perimeter Medical Imaging AI, Inc.
Adrian is an experienced technology executive with 25 years of
experience building and scaling technology companies across many
different industries. Most recently, he was Chief Operating Officer
at Groq Inc, an AI hardware company, which he joined shortly after
formation in 2016 and helped scale to one of the leading startups
in that space. Prior to Groq, Adrian spent several years both
investing in and founding technology focused companies in
North America and internationally
with a focus on helping them scale organizationally as well as
operationally. Adrian began his career at Cypress Semiconductor
where he spent 14 years leading various marketing, finance, and
operations functions. Adrian graduated from the University of Waterloo with a Bachelor's degree in
Electrical Engineering.
About Perimeter Medical Imaging AI, Inc.
Based
in Toronto, Canada and
Dallas, Texas, Perimeter
Medical Imaging AI (TSX-V: PINK) (OTC:
PYNKF) (FSE: 4PC) is a medical technology
company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level. The breakthrough-device-designated investigational Perimeter
B-Series OCT with ImgAssist AI represents our next-generation
artificial intelligence technology that is currently being
evaluated in a pivotal clinical trial, with support from a grant of
up to US$7.4 million awarded by the
Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a
reference to the pink ribbons used during Breast Cancer Awareness
Month.
Perimeter B-Series OCT is limited by U.S. law to
investigational use and not available for sale in the United States. Perimeter S-Series OCT has
510(k) clearance under a general indication and has not been
evaluated by the U.S. FDA specifically for use in breast tissue,
breast cancer, other types of cancer, margin evaluation, and
reducing re-excision rates. The safety and effectiveness of these
uses has not been established. For more information, please visit
www.perimetermed.com/disclosures.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains
statements that constitute "forward-looking information" within the
meaning of applicable Canadian securities legislation. In this news
release, words such as "may," "would," "could," "will," "likely,"
"believe," "expect," "anticipate," "intend," "plan," "estimate,"
and similar words and the negative form thereof are used to
identify forward-looking statements. Forward-looking information
may relate to management's future outlook and anticipated events or
results and may include statements or information regarding the
future financial position, business strategy and strategic goals,
competitive conditions, research and development activities,
projected costs and capital expenditures, research and clinical
testing outcomes, taxes and plans and objectives of, or involving,
Perimeter. Without limitation, information regarding expectations
regarding the future competitive landscape of the AI space,
expectations regarding Perimeter's business and the potential
benefits of Perimeter S-Series OCT and Perimeter B-Series OCT are
forward-looking information. Forward-looking statements should not
be read as guarantees of future performance or results, and will
not necessarily be accurate indications of whether, or the times at
or by which, any particular result will be achieved. No assurance
can be given that any events anticipated by the forward-looking
information will transpire or occur. Forward-looking information is
based on information available at the time and/or management's
good-faith belief with respect to future events and are subject to
known or unknown risks, uncertainties, assumptions, and other
unpredictable factors, many of which are beyond Perimeter's
control. Such forward-looking statements reflect Perimeter's
current view with respect to future events, but are inherently
subject to significant medical, scientific, business, economic,
competitive, political, and social uncertainties and contingencies.
In making forward-looking statements, Perimeter may make various
material assumptions, including but not limited to (i) the accuracy
of Perimeter's financial projections; (ii) obtaining positive
results from trials; (iii) obtaining necessary regulatory
approvals; and (iv) general business, market, and economic
conditions. Further risks, uncertainties and assumptions include,
but are not limited to, those applicable to Perimeter and described
in Perimeter's Management Discussion and Analysis for the year
ended December 31, 2023, which is
available on Perimeter's SEDAR+ profile at
https://www.sedarplus.ca, and could cause actual events or results
to differ materially from those projected in any forward-looking
statements. Perimeter does not intend, nor does Perimeter undertake
any obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View original
content:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-announces-webinar-featuring-ai-expert-anantha-kancherla-discussing-trends-in-the-use-of-machine-learning-and-artificial-intelligence-in-healthcare-applications-302117869.html
SOURCE Perimeter Medical Imaging AI, Inc.
